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Abstract
Background: Thiazolidine-2, 4-diones (TZDs) have become a pharmacologically important class of heterocyclic
compounds since their introduction in the form of glitazones into the clinical use for the treatment of type 2
diabetes. TZDs lower the plasma glucose levels by acting as ligands for gamma peroxisome proliferators-activated
receptors. In addition, this class of heterocyclic compounds possesses various other biological activities such as
antihyperglycemic, antimicrobial, anti-inflammatory, anticonvulsant, insecticidal, etc. TZDs are also known for
lowering the blood pressure thereby reducing the chances of heart failure and micro-albuminuria in the patients
with type 2 diabetes.
Results: We have described herein the synthesis of three series of compounds, namely, ethyl 2-((Z)-5-((3-aryl-1-
phenyl-1H-pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetates (4), methyl 2-((Z)-5-((3-aryl-1-phenyl-1H-pyrazol-
4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetates (5), and 2-((Z)-5-((3-aryl-1-phenyl-1H-pyrazol-4-yl)methylene)-2, 4-
dioxothiazolidin-3-yl)acetic acids (6). The compounds 4 and 5 were synthesized by Knoevenagel condensation
between 3-aryl-1-phenyl-1H-pyrazole-4-carbaldehydes (1) and ethyl/methyl 2-(2, 4-dioxothiazolidin-3-yl)acetates (3,
2) in alcohol using piperidine as a catalyst. The resultant compounds 4 and 5 having ester functionality were
subjected to acidic hydrolysis to obtain 6. All the new compounds were tested for their in vitro antibacterial and
antifungal activity.
Conclusions: Knoevenagel condensation approach has offered an easy access to new compounds 4-6.
Antimicrobial evaluation of the compounds has shown that some of the compounds are associated with
remarkable antifungal activity. In case of antibacterial activity, these were found to be effective against Gram-
positive bacteria. However, none of the compounds were found to be effective against Gram-negative bacteria.
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1. Background
Natural antibiotic compounds have become essential to
current health care system, assisting and complementing
the natural immune system against microbial pathogens.
As conventional antibiotics are often abused to treat
microbial infections, some microorganisms have devel-
oped tolerance to these antibiotics. Because of the
appearance of antibiotic-resistant strains, the continuous
development of novel efficient antibiotic agents is more
crucial than ever [1-3]. So, the medical community faces
a serious problem against infections caused by the
pathogen bacteria and needs an effective therapy and
search for novel antimicrobial agents. Synthetic organic
chemistry has always been a vital part of highly inte-
grated and multidisciplinary process of various drug
developments. In this context, this study was designed
to evaluate antimicrobial properties of new pyrazole
derivatives containing thiazolidindiones.
Pyrazole derivatives are known to possess wide spec-
trum of pharmacological properties such as antibacterial
[4-6], antifungal [7-9], antimicrobial [10-14], antidiabetic
[15], herbicidal [16,17], antitumor [18-21], anti-anxiety
[22], and as active pharmacophore in celecoxib (as
COX-2 inhibitor) [23] and slidenafil citrate [24] (as
cGMP specific phosphodiesterase type 5 inhibitor), etc.
Pyrazoles play an essential role in biological active
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plate for medicinal chemistry.
On the other hand, thiazolidines are also known for
their potential biological activities. The varied biological
activities of rhodanines (2-thioxo-thiazolidin-4-one) and
their analogs have been known from the beginning of
twentieth century. Rhodanines and 2, 4-thiazolidine-
diones (TZDs) have become a pharmacologically impor-
tant class of heterocyclic compounds since the
introduction of various glitazone and epalrestat into
clinical use for the treatment of type II diabetes and dia-
betic complications [25]. Several studies have been
reported that TZDs have acquired much importance
because of their diverse pharmaceutical applications
such as antihyperglycemic [26], bactericidal [27], pestici-
dal [28], fungicidal [29], insecticidal [30], anticonvulsant
[31], tuberculostatic [32], anti-inflammatory [33] etc.
Different possibilities of heterocyclic modifications
with a wide spectrum of pharmacological propertiesare
the most important grounds for investigation of this
class of compounds. There have been many reports in
literature depicting that the presence of heterocyclic
moieties such as thiazole, pyrazole, flavone, chromone,
sultam, and furan at fifth position proves to be more
potent and efficacious than a simple aryl group [34-39].
Although there are not many TZDs fused to pyrazoles,
a number of them are incorporated into a wide variety
of therapeutically important compounds possessing a
broad spectrum of biological activities. In a recent arti-
cle, pyrazolyl-2, 4-TZDs have been reported as anti-
inflammatory and neuroprotective agents.
M o t i v a t e db yt h e s ef i n d i n g sa n di nc o n t i n u a t i o no f
our ongoing efforts endowed with the discovery of
nitrogen-containing heterocycles with potential che-
motherapeutic activities [8,10,40-44], we disclose here
the synthesis and investigations of antimicrobial activ-
ities of new pyrazolyl-2, 4-TZD.
2. Results and discussion
2.1. Chemistry
The synthetic route for the preparation of ethyl 2-((Z)-
5-((3-aryl-1-phenyl-1H-pyrazol-4-yl)methylene)-2, 4-
dioxothiazolidin-3-yl)acetates (4a-h),m e t h y l2 - ( ( Z)-5-
((3-aryl-1-phenyl-1H-pyrazol-4-yl)methylene)-2, 4-diox-
othiazolidin-3-yl)acetates (5a-h), and 2-((Z)-5-((3-aryl-1-
phenyl-1H-pyrazol-4-yl)methylene)-2, 4-dioxothiazoli-
din-3-yl)acetic acids (6a-h) has been illustrated in
Scheme 1. Initially, Knoevenagel condensation was car-
ried out with equimolar ratio of ethyl 2-(2, 4-dioxothia-
zolidin-3-yl)acetate (3) and 1, 3-diphenyl-1H-pyrazole-4-
carbaldehyde (1a) in ethanol in presence of catalytic
amount of piperidine by refluxing for 5-6 h. The usual
work up of the reaction afforded the single product,
ethyl 2-((Z)-2, 4-dioxo-5-((1, 3-diphenyl-1H-pyrazol-4-
yl)methylene)thiazolidin-3-yl)acetate (4a) as yellow solid
in 90% yield. Similar method was adopted for the pre-
paration of 5a in methanol. The acid hydrolysis of 4a or
5a in acetic acid in the presence of dilute sulfuric acid
under refluxing for 5-6 h gave the desired product 2-
((Z)-2, 4-dioxo-5-((1, 3-diphenyl-1H-pyrazol-4-yl)methy-
lene)thiazolidin-3-yl)acetic acid (6a) in 94% yield.
All other compounds 4b-h, 5b-h,a n d6b-h were pre-
pared adopting the similar methodology. The physical
data of all compounds 4-6 have been summarized in
Table 1.
The structures of all compounds 4a-h, 5a-h, and 6a-h
were established by the spectral (IR, NMR {see addi-
t i o n a lf i l e s1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,1 0 ,1 1 ,1 2 ,1 3 ,1 4 ,1 5 ,
16, 17, 18, 19, 20, 21, 22, 23 and 24}, Mass) and elemen-
tal analysis. For example, IR spectrum of the compound
4a exhibited characteristic absorption bands at 1736 and
1690 cm
-1 because of carbonyl groups of ester and TZD.
The
1H NMR spectrum of the product 4a (see addi-
tional files 1) showed three characteristic singlets at δ
8.213, δ 7.963, and δ 4.473 because of C(5)-H of pyra-
zole ring, =CH and -NCH2, respectively, apart from
other aromatic signals. Besides these the aliphatic region
also showed the characteristic quartet and triplet due to
-OCH2CH3 at δ 4.248 and δ 1.301, respectively. The
product 6a was characterized by careful comparison of
the IR and
1H NMR spectra (see additional file 17) with
those of the 4a. An important characteristic feature in
1HN M Rs p e c t r u mo f6a was disappearance of the tri-
plet and quartet in the aliphatic region which was pre-
sent in the spectrum of 4a.
The starting materials 3-aryl-1-phenyl-1H-pyrazole-4-
carbaldehydes (1a-h) were prepared according to litera-
ture procedure involving Vilsmeier-Haack reaction of
Scheme 1 Synthesis of pyrazolyl-2, 4-TZDs (4-6).
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Page 2 of 11various substituted acetophenone hydrazones using
POCl3/DMF at 50-60°C for 4-5 h [45-47] and ethyl/
methyl 2-(2, 4-dioxothiazolidin-3-yl)acetates (3, 2)w e r e
prepared in multiple steps by alkylation of potassium
salt of thiazolidine-2, 4-dione (TZDs) with appropriate
alkyl 2-bromoacetate either in acetone at 50°C for 5 h
or in KI/DMF at 90°C for 12 h [48]. The key starting
material 2, 4-TZD needed for this purpose was obtained
in one step from equimolar amounts of chloroacetic
acid and thiourea under ice cold condition. The white
precipitate of 2-imino thiazolidine-4-one obtained was
then acidified and refluxed with HCl for 12 h to get
white crystals of 2, 4-TZD [49].
Although geometrical isomerism (E/Z isomers) was
possible because of restricted rotation about the exocyc-
lic C=C bond of the pyrazolyl-2, 4-TZDs, all the deriva-
tives prepared in this study were obtained exclusively in
Z-form as confirmed by the analytical data. The
1H
NMR spectra of the pyrazolyl-2, 4-TZDs (see additional
f i l e s1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,1 0 ,1 1 ,1 2 ,1 3 ,1 4 ,1 5 ,1 6 ,1 7 ,
18, 19, 20, 21, 22, 23, 24) showed that the most charac-
teristic olefinic proton =CH was deshielded more (δ =
7.3-7.6 ppm) as expected in Z-form, relative to the
slightly shielded protons of the E-form (δ = 6.2-6.3 ppm,
in case of various other arylidene-2, 4-TZD). This
deshielding of the olefinic proton is caused by the
anisotropic effect exerted by the nearby carbonyl group
of the 2, 4-TZDs in Z-isomer. Furthermore, the Z-iso-
mers are thermodynamic more stable because of intra-
molecular hydrogen bond that can be formed between
t h eh y d r o g e nb o n do f= C Ha n do x y g e na t o mi nT Z D
[50,51].
2.2. Pharmacology
2.2.1. In vitro antifungal activity
All the 24 compounds were tested for their in vitro anti-
fungal activity against two fungi, namely, Aspergillus
niger and Aspergillus flavus. Standard antibiotic, namely,
Fluconazole, was used for comparison with antifungal
activity shown by compounds 4a-h, 5a-h,a n d6a-h.A
careful analysis of percentage mycelial growth inhibition
revealed that almost all the newly synthesized com-
pounds showed comparable antifungal activity with
commercial antibiotics Fluconazole as shown in Table 2.
Compounds 4b and 4e showed maximum inhibition
against A. niger (70%) and A. flavus (67.7%), respectively.
Eleven compounds 4d, 4e, 4g, 5a, 5h, 6a, 6b, 6d, 6e, 6f,
and 6h showed more than 60% inhibition against A. fla-
vus in comparison to 77.7% of Fluconazole. Eleven com-
pounds which showed more than 60% inhibition against
Table 1 Physical data of the compounds 4-6
Compounds Yields (%) Melting points (°C)
4a 90 223-225
4b 92 225-227
4c 91 274-276
4d 92 248-250
4e 93 237-239
4f 93 258-260
4g 94 248-250
4h 95 231-233
5a 92 225-227
5b 94 233-235
5c 91 263-265
5d 93 248-250
5e 91 233-235
5f 92 269-271
5g 90 280-282
5h 93 240-242
6a 94 294-296
6b 93 300-302
6c 94 262-264
6d 93 280-282
6e 92 304-306
6f 90 288-290
6g 94 317-319
6h 91 287-288 Table 2 In vitro antifungal activity of the compounds 4-6
Compounds Mycelial growth of inhibition (%)
A. flavus A. niger
4a 54.4 60.0
4b 54.4 70.0
4c 48.8 54.4
4d 61.1 65.5
4e 67.7 61.1
4f 55.5 62.5
4g 61.1 54.4
4h 48.8 58.8
5a 62.5 55.5
5b 48.8 54.4
5c 54.4 62.5
5d 55.5 61.1
5e 57.7 55.5
5f 67.7 62.5
5g 54.4 57.7
5h 61.1 54.4
6a 61.1 62.5
6b 63.3 61.1
6c 55.5 60.0
6d 61.5 62.5
6e 65.5 62.5
6f 65.5 61.1
6g 54.4 58.8
6h 61.1 60.0
Fluconazole 77.7 81.1
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After all, the compounds which showed more than 60%
inhibition against both the pathogenic fungi are 4a, 4e,
6a, 6d, and 6e.
2.2.2. In vitro antibacterial activity
All the 24 compounds 4a-h, 5a-h,a n d6a-h were tested
in vitro for their antibacterial activity against two Gram-
positive bacteria, namely, Staphylococcus aureus (MTCC
96), Bacillus subtillis (MTCC 121) and two Gram-nega-
tive bacteria, namely, Escherichia coli (MTCC 1652),
and Pseudomonas aeruginosa (MTCC 741) (Tables 3
and 4). Minimum inhibitory concentrations (MIC) of
those compounds were determined which were showing
activity in primary screening. Standard antibiotic, Cipro-
floxacin, was used for comparison with antibacterial
activity shown by the compounds 4a-h, 5a-h, and 6a-h.
All compounds of the tested series showed variable
antibacterial activity against Gram-positive bacteria.
Three of the tested compounds 5h, 6a, and 6h exhibited
good antibacterial activity against Gram-positive bac-
teria. However, none of the compounds showed activity
against Gram-negative bacteria.
In case of Gram-positive bacteria, compounds 4h, 5b,
5h, 6a, 6b,a n d6h w e r ef o u n dt ob em o s te f f e c t i v e
against S. aureus with zone of inhibition ranging
between 18.6 mm and 20.0 mm and the compounds 5h,
6a,a n d6b were most effective against B. subtillis with
zone of inhibition ranging between 19.3 mm and 21.0
mm (Table 3).
In whole series, compounds 4a, 4h,a n d5h showed
maximum antibacterial activity against S. aureus (MIC
64 μg/mL) and compounds 5h (MIC 32 μg/mL), 6a
&6h (MIC 64 μg/mL) against B. subtillis (Table 4).
3. Conclusions
We have described herein an efficient and convenient
synthesis of three series of pyrazolyl-2, 4-TZDs (4-6)b y
Knoevenagel condensation. All the 24 compounds
synthesized were characterized by spectral and elemental
analytical data and evaluated for their in vitro antifungal
and antibacterial activities. Results of the antifungal
activity were found to be comparable with the reference
compound. On the other hand, antibacterial activity was
best observed for Gram-positive bacteria only, none of
the compounds showed activity against Gram-negative
bacteria.
Table 3 In vitro antibacterial activity of the compounds
4-6
Compounds Diameter of the growth of zone inhibition (mm)
a
S. aureus B. subtilis
4a 15.6 16.3
4b 16.3 15.0
4c 15.3 14.6
4d 14.3 14.6
4e 13.6 14.0
4f 16.6 17.6
4g 15.0 15.6
4h 19.0 17.0
5a 17.6 15.3
5b 18.6 16.0
5c 15.6 15.0
5d 16.3 15.6
5e 15.0 16.6
5f 16.6 16.6
5g 18.0 16.0
5h 20.0 21.0
6a 18.6 19.3
6b 18.6 19.3
6c 14.0 15.3
6d 16.6 17.3
6e 14.6 13.0
6f 13.6 14.3
6g 13.6 14.6
6h 19.0 18.0
Ciprofloxacin 26.0 24.0
aValues including diameter of the well (8 mm) are means of three replicates
Table 4 MIC of the compounds 4-6
Compounds MIC (μg/mL)
S. aureus B. subtilis
4a 128 128
4b 128 128
4c 128 128
4d 128 128
4e 128 128
4f 128 128
4g 128 128
4h 64 128
5a 128 128
5b 128 128
5c 128 128
5d 128 128
5e 128 128
5f 128 128
5g 64 128
5h 64 32
6a 64 64
6b 128 64
6c 128 128
6d 128 128
6e 128 128
6f 128 128
6g 128 128
6h 64 64
Ciprofloxacin 55
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4.1. General remarks
Melting points (mps) were taken on slides in an electri-
cal apparatus Labindia visual melting range apparatus
and are uncorrected. Calibration of melting point appa-
ratus was done using benzoic acid as reference. IR spec-
tra were recorded on a Perkin-Elmer 1800 FT-IR
spectrophotometer.
1H NMR spectra (see additional files
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23, 24) were recorded on a Bruker 300 &
400 MHz instrument using tetramethylsilane as an
internal standard. Mass spectra were recorded on 2500
eV (ESI Source) using a water’sQ - T O Fm i c r o i n s t r u -
ment and elemental analysis on Perkin-Elmer 2400
instrument. All the reagents were purchased from the
commercial sources and were used without further
purification.
4.2. Preparation of ethyl 2-((Z)-5-((3-aryl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetates
(4a-h)
Typical procedure: A mixture of 1, 3-diphenyl-1H-pyra-
zol-4-carboxaldehyde 1a (0.5 g, 2 mmol) and ethyl 2-(2,
4-dioxothiazolidin-3-yl)acetate 3 (0.4 g, 2 mmol) in
ethanol (20 mL) and 2-3 drops of piperidine was
refluxed for 4-5 h. A solid was separated out of the
reaction mixture within 15-20 min and the refluxing
was continued for 4-5 h to complete the reaction. The
reaction mixture was cooled to room temperature, fil-
tered, and washed with ethanol to give the pure product
4a (0.87 g, 90% yield).
The other derivatives 4b-h were synthesized by adopt-
ing the similar procedure.
4.3. Ethyl 2-((Z)-2, 4-dioxo-5-((1, 3-diphenyl-1H-pyrazol-4-
yl)methylene)thiazolidin-3-yl)acetate (4a)
IR (νmax, KBr) cm
-1: 1736, 1690, 1612, 1535, 1504, 1450,
1373, 1311, 1227, 1142, 1103, 1065, 1026.
1HN M R
(CDCl3, 400 MHz, δ): 8.213 (s, 1H, Pyrazolyl H), 7.963
(s, 1H, =CH), 7.817-7.795 (m, 2H, Ar H), 7.678-7.654
(m, 2H, Ar H), 7.549-7.471 (m, 5H, Ar H), 7.414-7.377
(m, 1H, Ar H), 4.473 (s, 2H, NCH2), 4.275-4.222 (q, 2H,
-OCH2CH3), 1.319-1.283 (t, 3H, -OCH2CH3). MS (ESI+)
m/z 434 [M+H]. Anal. Found: C, 63.3; H, 4.6; N, 9.5.
C23H19N3O4S requires C, 63.73; H, 4.42; N, 9.69%.
4.4. Ethyl 2-((Z)-2, 4-dioxo-5-((1-phenyl-3-p-tolyl-1H-
pyrazol-4-yl)methylene)thiazolidin-3-yl)acetate (4b)
IR (νmax, KBr) cm
-1: 1736, 1690, 1605, 1520, 1450, 1373,
1311, 1219, 1142, 1095, 1026.
1H NMR (DMSO-d6, 400
MHz, δ): 8.812 (s, 1H, Pyrazolyl H), 8.041-8.022 (m, 2H,
Ar H), 7.739 (s, 1H, =CH) 7.598-7.536 (m, 4H, Ar H),
7.448-7.379 (m, 3H, Ar H), 4.480 (s, 2H, NCH2), 4.199-
4.145 (q, 2H, -OCH2CH3), 2.405 (s, 3H, Ph CH3), 1.231-
1.195 (t, 3H, -OCH2CH3). MS (ESI+) m/z 448 [M+H].
Anal. Found: C, 64.0; H, 4.98; N, 9.2. C24H21N3O4S
requires C, 64.41; H, 4.73, N, 9.39%.
4.5. Ethyl 2-((Z)-5-((3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(4c)
IR (νmax, KBr) cm
-1: 1736, 1690, 1612, 1520, 1450, 1373,
1311, 1296, 1227, 1180, 1142, 1095, 1026, 1018.
1H
NMR (TFA-d1,4 0 0M H z ,δ): 8.483 (s, 1H, Pyrazolyl H),
7.917 (s, 1H, =CH), 7.667-7.583 (m, 7H, Ar H), 7.179-
7.157 (d, 2H, Ar H, J = 8.8 Hz), 4.620 (s, 2H, NCH2),
4.345-4.291 (q, 2H, CH2CH3), 3.922 (s, 3H, Ph OCH3),
1.304-1.269 (t, 3H, CH3CH2). MS (ESI+) m/z 464 [M
+H]. Anal. Found: C, 61.8; H, 4.1; N, 8.6. C24H21N3O5S
requires C, 62.19; H, 4.57; N, 9.07%.
4.6. Ethyl 2-((Z)-5-((3-(4-chlorophenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(4d)
IR (νmax,K B r )c m
-1: 1736, 1690, 1612, 1528, 1443,
1373, 1311, 1227, 1142, 1095, 1011.
1HN M R( T F A - d 1,
400 MHz, δ): 8.657 (s, 1H, Pyrazolyl H), 8.052 (s, 1H,
=CH), 7.832-7.748 (m, 5H, Ar H), 7.748-7.724 (m, 4H,
A rH ) ,4 . 7 8 9( s ,2 H ,N C H 2), 4.515-4.462 (q, 2H,
-OCH2CH3), 1.476-1.440 (t, 3H, -OCH2CH3). MS (ESI
+) m/z 454 [M+H]. Anal. Found: C, 58.6; H, 3.9; N,
8.7. C23H18ClN3O4S requires C, 59.04; H, 3.88; N,
8.98%.
4.7. Ethyl 2-((Z)-5-((3-(4-fluorophenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(4e)
IR (νmax, KBr) cm
-1: 1736, 1697, 1612, 1512, 1450, 1373,
1311, 1234, 1142, 1095, 1026.
1HN M R( T F A - d 1,4 0 0
MHz, δ): 8.489 (s, 1H, Pyrazolyl H), 7.884 (s, 1H, =CH),
7.652-7.584 (m, 7H, Ar H), 7.290-7.247 (m, 2H, Ar H),
4.624 (s, 2H, NCH2), 4.351-4.297 (q, 2H, -OCH2CH3),
1.311-1.275 (t, 3H, -OCH2CH3). MS (ESI+) m/z 437 [M
+H]. Anal. Found: C, 61.0; H, 4.2; N, 9.2. C23H18FN3O4S
requires C, 61.19; H, 4.02; N, 9.31%.
4.8. Ethyl 2-((Z)-5-((3-(4-bromophenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(4f)
IR (νmax, KBr) cm
-1: 1736, 1690, 1605, 1528, 1443, 1373,
1311, 1227, 1142, 1095, 1003.
1HN M R( T F A - d 1,4 0 0
MHz, δ): 8.488 (s, 1H, Pyrazolyl H), 7.896 (s, 1H, =CH),
7.750-7.729 (m, 2H, Ar H), 7.650-7.588 (m, 5H, Ar H),
7.489-7.467 (d, 2H, Ar H, J = 8.8 Hz) 4.633 (s, 2H,
NCH2), 4.359-4.305 (q, 2H, -OCH2CH3), 1.319-1.283 (t,
3H, -OCH2CH3). MS (ESI+) m/z 497 [M+H]. Anal.
Found: C, 53.7; H, 3.4; N, 8.0. C23H18BrN3O4Sr e q u i r e s
C, 53.91; H, 3.54; N, 8.20%.
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Page 5 of 114.9. Ethyl 2-((Z)-5-((3-(4-hydroxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(4g)
IR (νmax, KBr) cm
-1: 3387, 1736, 1682, 1605, 1520, 1373,
1319, 1234, 1142, 1103, 1026.
1H NMR (DMSO-d6, 400
MHz, δ): 9.850 (bs, 1H, OH), 8.773 (s, 1H, Pyrazolyl H),
8.027-8.007 (m, 2H, Ar H), 7.734 (s, 1H, =CH), 7.588-
7.549 (m, 2H, Ar H), 7.474-7.452 (d, 2H, Ar H, J =8 . 8
Hz), 7.435-7.398 (m, 1H, Ar H), 6.955-6.933 (d, 2H, Ar
H, J = 8.8 Hz), 4.479 (s, 2H, NCH2), 4.199-4.146 (q, 2H,
-OCH2CH3), 1.232-1.196 (t, 3H, -OCH2CH3). MS (ESI+)
m/z 435 [M+H]. Anal. Found: C, 61.3; H, 4.4; N, 9.1.
C23H19N3O5S requires C, 61.46; H, 4.26; N, 9.35%.
4.10. Ethyl 2-((Z)-5-((3-(4-nitrophenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(4h)
IR (νmax, KBr) cm
-1: 1736, 1697, 1620, 1528, 1350, 1319,
1234, 1142, 1095.
1HN M R( T F A - d 1, 400 MHz, δ):
8.482-8.460 (d, 2H, Ar H, J = 8.8 Hz), 8.391 (s, 1H, Pyr-
azolyl H), 7.957 (s, 1H, =CH), 7.895-7.874 (d, 2H, Ar H,
J = 8.4 Hz), 7.664-7.652 (m, 2H, Ar H), 7.586-7.573 (m,
3H, Ar H), 4.666 (s, 2H, NCH2), 4.388-4.334 (q, 2H,
-OCH2CH3), 1.347-1.311 (t, 3H, -OCH2CH3). MS (ESI+)
m/z 465 [M+H]. Anal. Found: C, 57.4; H, 3.9; N, 11.6.
C23H18N4O6S requires C, 57.73; H, 3.79; N, 11.71%.
4.11. Preparation of methyl 2-((Z)-5-((3-aryl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetates
(5a-h)
Typical procedure: A mixture of 1, 3-diphenyl-1H-pyra-
zol-4-carboxaldehyde 1a (0.5 g, 2 mmol) and methyl 2-
(2, 4-dioxothiazolidin-3-yl)acetate 2 (0.38 g, 2 mmol) in
methanol (20 ml) and 2-3 drops of piperidine was
refluxed 4-5 h. A solid was separated out of the reaction
mixture within 15-20 min and the refluxing was contin-
ued for 4-5 h to complete the reaction. The reaction
mixture was cooled to room temperature, filtered and
washed with methanol to give the pure product 5a (0.84
g, 92% yield).
The other derivatives 5b-h were synthesized by adopt-
ing the similar procedure.
4.12. Methyl 2-((Z)-2, 4-dioxo-5-((1, 3-diphenyl-1H-pyrazol-
4-yl)methylene)thiazolidin-3-yl)acetate (5a)
IR (νmax,K B r )c m
-1: 1744, 1690, 1605, 1535, 1443,
1366, 1311, 1234, 1142, 1103, 1011.
1H NMR (DMSO-
d6, 400 MHz, δ): 8.828 (s, 1H, Pyrazolyl H), 8.069-
8.029 (m, 2H, Ar H), 7.745 (s, 1H, =CH), 7.685-7.649
(m, 2H, Ar H), 7.601-7.537 (m, 5H, Ar H), 7.453-7.417
(m, 1H, Ar H), 4.501 (s, 2H, NCH2), 3.711 (s, 3H,
COOCH3). MS (ESI+) m/z 406 [M+H]. Anal. Found:
C, 62.7; H, 4.2; N, 9.9. C22H17N3O4Sr e q u i r e sC ,6 3 . 0 0 ;
H, 4.09; N, 10.02%.
4.13. Methyl 2-((Z)-2, 4-dioxo-5-((1-phenyl-3-p-tolyl-1H-
pyrazol-4-yl)methylene)thiazolidin-3-yl)acetate (5b)
IR (νmax, KBr) cm
-1: 1744, 1690, 1605, 1512, 1443, 1366,
1319, 1234, 1142, 1103, 1011.
1HN M R( T F A - d 1,4 0 0
MHz, δ): 8.501 (s, 1H, Pyrazolyl H), 7.924 (s, 1H, =CH),
7.626 (m, 5H, Ar H), 7.492-7.472 (m, 2H, Ar H), 7.417-
7.398 (m, 2H, Ar H), 4.632 (s, 2H, NCH2), 3.711 (s, 3H,
COOCH3), 2.404 (s, 3H, Ph CH3). MS (ESI+) m/z 419
[M+H]. Anal. Found: C, 63.6; H, 4.5; N, 9.4.
C23H19N3O4S requires C, 63.73; H, 4.42; N, 9.69%.
4.14. Methyl 2-((Z)-5-((3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(5c)
IR (νmax, KBr) cm
-1: 1744, 1690, 1612, 1520, 1443, 1366,
1296, 1242, 1180, 1142, 1103, 1018.
1HN M R( T F A - d 1,
400 MHz, δ): 8.477 (s, 1H, Pyrazolyl H), 7.915 (s, 1H,
=CH), 7.665-7.568 (m, 6H, Ar H), 7.178-7.156 (d, 2H,
Ar H, J = 8.8 Hz), 4.630 (s, 2H, NCH2), 3.923 (s, 3H,
COOCH3), 3.859 (s, 3H, Ph OCH3). MS (ESI+) m/z 436
[M+H]. Anal. Found: C, 61.3; H, 4.4; N, 9.2.
C23H19N3O5S requires C, 61.46; H, 4.26; N, 9.35%.
4.15. Methyl 2-((Z)-5-((3-(4-chlorophenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate
(5d)
IR (νmax, KBr) cm
-1: 1744, 1697, 1605, 1528, 1443, 1366,
1319, 1242, 1142, 1103, 1011.
1HN M R( T F A - d 1,4 0 0
MHz, δ): 8.476 (s, 1H, Pyrazolyl H), 7.884 (s, 1H, =CH),
7.618-7.552 (m, 9H, Ar H), 4.630 (s, 2H, NCH2), 3.861
(s, 3H, COOCH3). MS (ESI+) m/z 440 [M+H]. Anal.
Found: C, 58.0; H, 3.6; N, 9.1. C22H16N3O4S requires C,
58.21; H, 3.55; N, 9.26%.
Methyl 2-((Z)-5-((3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-
yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate (5e)
IR (νmax, KBr) cm
-1: 1744, 1697, 1612, 1520, 1404, 1366,
1319, 1234, 1149, 1095.
1H NMR (TFA-d1, 400 MHz, δ):
8.494 (s, 1H, Pyrazolyl H), 7.893 (s, 1H, =CH), 7.650-
7.616 (m, 7H, Ar H), 7.300-7.258 (m, 2H, Ar H), 4.663
(s, 2H, NCH2), 3.876 (s, 3H, COOCH3). MS (ESI+) m/z
424 [M+H]. Anal. Found: C, 60.2; H, 3.8; N, 9.5.
C22H16FN3O4S requires C, 60.40; H, 3.69; N, 9.61%.
Methyl 2-((Z)-5-((3-(4-bromophenyl)-1-phenyl-1H-pyrazol-
4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate (5f)
IR (νmax, KBr) cm
-1: 1744, 1697, 1612, 1520, 1404, 1366,
1319, 1234, 1149, 1095.
1H NMR (CDCl3 + TFA-d1, 400
MHz, δ): 8.250 (s, 1H, Pyrazolyl H), 7.899 (s, 1H, =CH),
7.750-7.730 (d, 2H, Ar H, J = 8.0 Hz), 7.660-7.611 (m,
5H, Ar H), 7.500-7.480 (d, 2H, Ar H, J = 8.00 Hz), 4.652
(s, 2H, NCH2), 3.901 (s, 3H, COOCH3). MS (ESI+) m/z
483 [M+H]. Anal. Found: C, 52.9; H, 3.4; N, 8.2.
C22H16BrN3O4S requires C, 53.02; H, 3.24; N, 8.43%.
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4-yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate (5g)
IR (νmax, KBr) cm
-1: 3348, 1736, 1682, 1605, 1512, 1443,
1412, 1373, 1311, 1234, 1211, 1142, 1103.
1HN M R
(DMSO-d6, 400 MHz, δ): 9.863 (s, 1H, Ph OH), 8.764 (s,
1 H ,P y r a z o l y lH ) ,8 . 0 2 3 - 8 . 0 0 3( m ,2 H ,A rH ) ,7 . 7 3 0( s ,
1H, =CH), 7.585-7.546 (m, 2H, Ar H), 7.471-7.450 (d,
2H, Ar H, J = 8.4 Hz), 7.434-7.395 (m, 1H, Ar H),
6.954-6.933 (d, 2H, Ar H, J = 8.4 Hz), 4.499 (s, 2H,
NCH2), 3.712 (s, 3H, COOCH3). MS (ESI+) m/z 450 [M
+H]. Anal. Found: C, 60.5; H, 4.0; N, 9.5. C22H17N3O5S
requires C, 60.68; H, 3.93; N, 9.65%.
Methyl 2-((Z)-5-((3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-
yl)methylene)-2, 4-dioxothiazolidin-3-yl)acetate (5h)
IR (νmax, KBr) cm
-1: 1744, 1690, 1605, 1528, 1412, 1342,
1273, 1219, 1142, 1103.
1H NMR (CDCl3 + TFA-d1, 400
MHz, δ): 8.454-8.434 (d, 2H, Ar H, J = 8.8 Hz), 8.261-
8.247 (m, 2H, Ar H), 7.906-7.834 (m, 3H, Ar H), 7.710-
7.689 (m, 2H, Ar H), 7.637-7.571 (m, 2H, Ar H), 4.642
(s, 2H, NCH2), 3.985 (s, 3H, COOCH3). MS (ESI+) m/z
450 [M+H]. Anal. Found: C, 58.7; H, 3.6; N, 11.8.
C22H16N4O6S requires C, 58.89; H, 3.47; N, 12.06%.
Preparation of 2-((Z)-5-((3-aryl-1-phenyl-1H-pyrazol-4-yl)
methylene)-2, 4-dioxothiazolidin-3-yl)acetic acid (6a-h)
Typical procedure: A mixture of ethyl 2-((Z)-2, 4-dioxo-
5-((1, 3-diphenyl-1H-pyrazol-4-yl)methylene)thiazolidin-
3-yl)acetate 4a (0.5g, 1.1 mmol), 10 mL of 50% aqueous
sulphuric acid in 35 mL acetic acid was refluxed for 5-6
h. On cooling, the reaction mixture was poured onto
crushed ice. Solid separated was filtered, washed with
excess of cold water followed by alcohol to obtain white
solid 6a (0.47g, 94%). Similarly, 6a can also be obtained
from 5a by hydrolysis.
All other derivatives 6b-h were synthesized by adopt-
ing the similar procedure.
2-((Z)-2, 4-Dioxo-5-((1, 3-diphenyl-1H-pyrazol-4-yl)
methylene)thiazolidin-3-yl)acetic acid (6a)
IR (νmax, KBr) cm
-1: 3472, 3418, 1744, 1697, 1605, 1528,
1504, 1443, 1373, 1319, 1219, 1149, 1103, 1102, 1057,
1003.
1H NMR (DMSO-d6,3 0 0M H z ,δ): 8.807 (s, 1H,
Pyrazolyl H), 8.040-8.018 (m, 2H, Ar H), 7.729-7.434
( m ,9 H ,A r H+= C H ) ,4 . 3 5 9( s ,2 H ,N C H 2). MS (ESI+)
m/z 392 [M+H]. Anal. Found: C, 62.1; H, 3.8; N, 10.2.
C21H15N3O4S requires C, 62.21; H, 3.73; N, 10.36%.
2-((Z)-2, 4-Dioxo-5-((1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)
methylene)thiazolidin-3-yl)acetic acid (6b)
IR (νmax, KBr) cm
-1: 1744, 1697, 1605, 1512, 1450, 1389,
1319, 1227, 1149, 1103, 1003.
1H NMR (DMSO-d6, 300
MHz, δ): 8.795 (s, 1H, Pyrazolyl H), 8.045-8.015 (m, 2H,
Ar H), 7.727 (s, 1H, =CH), 7.603-7.530 (m, 4H, Ar H),
7.451-7.373 (m, 3H, Ar H), 4.366 (s, 2H, NCH2), 2.405
(s, 3H, CH3). MS (ESI+) m/z 406 [M+H]. Anal. Found:
C ,6 2 . 8 ;H ,4 . 2 ;N ,9 . 9 .C 22H17N3O4S requires C, 63.00;
H, 4.09; N, 10.02%.
2-((Z)-5-((3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-2, 4-dioxothiazolidin-3-yl)acetic acid (6c)
IR (νmax,K B r )c m
-1: 1736, 1690, 1612, 1520, 1450, 1396,
1296, 1242, 1180, 1142, 1103, 1018.
1H NMR (DMSO-d6,
300 MHz, δ): 8.782 (s, 1H, Pyrazolyl H), 8.037-8.011 (m,
2H, Ar H), 7.722 (s, 1H, =CH), 7.599-7.548 (m, 4H, Ar H),
7.447-7.398 (m, 1H, Ar H), 7.149-7.120 (d, 2H, Ar H, J =
8 . 7H z ) ,4 . 3 6 5( s ,2 H ,N C H 2), 3.842 (s, 3H, OCH3). MS
(ESI+) m/z 422 [M+H]. Anal. Found: C, 60.5; H, 3.8, N,
14.20. C22H17N3O5S requires C, 60.68; H, 3.93; N, 9.65%.
2-((Z)-5-((3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-2, 4-dioxothiazolidin-3-yl)acetic acid (6d)
IR (νmax, KBr) cm
-1: 3472, 3418, 1736, 1690, 1612, 1520,
1450, 1396, 1296, 1242, 1180, 1142, 1103, 1018.
1H
NMR (DMSO-d6,3 0 0M H z ,δ): 8.776 (s, 1H, Pyrazolyl
H), 8.006-7.980 (d, 2H, Ar H, J = 7.8 Hz), 7.687 (s, 1H,
=CH), 7.656-7.544 (m, 6H, Ar H), 7.449-7.365 (m, 1H,
Ar H), 4.350 (s, 2H, NCH2). MS (ESI+) m/z 426 [M+H].
Anal. Found: C, 57.0; H, 3.4; N, 9.4. C21H14ClN3O4S
requires C, 57.34; H, 3.21; N, 9.55%.
2-((Z)-5-((3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-2, 4-dioxothiazolidin-3-yl)acetic acid (6e)
IR (νmax, KBr) cm
-1: 1751, 1697, 1612, 1512, 1450, 1373,
1319, 1227, 1149, 1095, 1003.
1H NMR (DMSO-d6, 300
MHz, δ): 8.819 (s, 1H, Pyrazolyl H), 8.048-8.022 (d, 2H,
Ar H, J = 7.8 Hz), 7.737-7.711 (m, 3H, =CH and Ar H),
7.607-7.556 (m, 2H, Ar H), 7.455-7.396 (m, 3H, Ar H),
4.369 (s, 2H, NCH2). MS (ESI+) m/z 410 [M+H]. Anal.
Found: C, 59.4; H, 3.5; N, 9.8. C21H14FN3O4Sr e q u i r e s
C, 59.57; H, 3.33; N, 9.92%.
2-((Z)-5-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-2, 4-dioxothiazolidin-3-yl)acetic acid (6f)
IR (νmax, KBr) cm
-1: 1744, 1697, 1605, 1528, 1504, 1443,
1389, 1319, 1242, 1149, 1103, 1003.
1HN M R( D M S O -
d6, 300 MHz, δ): 8.822 (s, 1H, Pyrazolyl H), 8.039-8.013
(m, 2H, Ar H), 7.798-7.771 (d, 2H, Ar H, J =8 . 1H z ) ,
7.712 (s, 1H, =CH), 7.634-7.607 (d, 2H, Ar H, J =8 . 1
Hz), 7.581-7.555 (m, 2H, Ar H), 7.460-7.413 (m, 1H, Ar
H), 4.372 (s, 2H, NCH2). MS (ESI+) m/z 470 [M+H].
Anal. Found: C, 51.9; H, 2.8; N, 8.5. C21H14BrN3O4S
requires C, 52.08; H, 2.91; N, 8.68%.
2-((Z)-5-((3-(4-Hydroxyphenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-2, 4-dioxothiazolidin-3-yl)acetic acid (6g)
IR (νmax, KBr) cm
-1: 3379, 3310, 1736, 1713, 1674, 1605,
1512, 1443, 1404, 1373, 1219, 1142, 1103, 1057, 1003.
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OH), 8.753 (s, 1H, Pyrazolyl H), 8.026-8.000 (d, 2H, Ar
H, J = 7.8 Hz), 7.721 (s, 1H, =CH), 7.591-7.540 (m, 2H,
Ar H), 7.476-7.388 (m, 3H, Ar H), 6.960-6.933 (d, 2H,
Ar H, J = 8.1 Hz), 4.361 (s, 2H, NCH2). MS (ESI+) m/z
408 [M+H]. Anal. Found: C, 59.7; H, 3.7; N, 9.8.
C21H15N3O5S requires C, 59.85; H, 3.59; N, 9.97%.
2-((Z)-5-((3-(4-Nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-2, 4-dioxothiazolidin-3-yl)acetic acid (6h)
IR (νmax,K B r )c m
-1: 3418, 3479, 1774, 1728, 1674, 1605,
1528, 1404, 1350, 1242, 1180, 1142, 1103 1065.
1HN M R
(DMSO-d6,3 0 0M H z ,δ): 8.887 (s, 1H, Pyrazolyl H),
8.433-8.404 (d, 2H, Ar H, J = 8.7 Hz), 8.066-8.039 (d, 2H,
Ar H, J = 8.1 Hz), 7.983-7.954 (d, 2H, Ar H, J =8 . 7H z ) ,
7.763 (s, 1H, =CH), 7.622-7.571 (m, 2H, Ar H), 7.482-
7.434 (m, 1H, Ar H), 4.384 (s, 2H, NCH2). MS (ESI+) m/
z 4 5 1[ M + H ] .A n a l .F o u n d :C ,5 5 . 8 ;H ,3 . 0 ;N ,1 2 . 3 .
C21H14N4O6S requires C, 56.00; H, 3.13; N, 12.44%.
Biological assay
Test microorganisms
Four bacteria, S. aureus (MTCC 96), B. subtilis (MTCC
121) (Gram-positive), E. coli (MTCC 1652) and P. aeru-
ginosa (MTCC 741) (Gram-negative) procured from
MTCC, Chandigarh and two fungi, A. niger and A. fla-
vus, the ear pathogens isolated from the Kurukshetra
patients, were used in this study [52].
In vitro antibacterial activity
The antibacterial activity of synthesized compounds was
evaluated by the agar well-diffusion method. All the cul-
tures were adjusted to 0.5 McFarland standard, which is
visually comparable to a microbial suspension of
approximately 1.5 × 10
8 cfu/mL. 20-mL of Mueller Hin-
ton agar medium was poured into each Petri plate and
the agar plates were swabbed with 100 μLi n o c u l ao f
each test bacterium and kept for 15 min for adsorption.
Using sterile cork borer of 8-mm diameter, wells were
bored into the seeded agar plates and these were loaded
with a 100-μL volume with concentration of 4.0 mg/mL
of each compound reconstituted in the dimethylsulph-
oxide (DMSO). All the plates were incubated at 37°C
for 24 h. Antibacterial activity of each synthetic com-
pound was evaluated by measuring the zone of growth
inhibition against the test organisms with zone reader
(Hi Antibiotic zone scale). DMSO was used as a nega-
tive control whereas ciprofloxacin was used as a positive
control. This procedure was performed in three replicate
plates for each organism [53].
Determination of MIC
MIC is the lowest concentration of an antimicrobial com-
pound that will inhibit the visible growth of a
microorganism after overnight incubation. MIC of the var-
ious compounds against bacterial strains was tested
through a macro dilution tube method as recommended
by NCCLS [54]. In this method, various test concentra-
tions of synthesized compounds were made from 128 to
0.25 μg/mL in sterile tubes no. 1 to 10. 100-μLs t e r i l e
Mueller Hinton Broth (MHB) was poured in each sterile
tube followed by addition of 200 μLt e s tc o m p o u n di n
tube 1. Twofold serial dilutions were carried out from the
tube no. 1 to the tube no. 10 and excess broth (100 μL)
was discarded from the last tube no. 10. To each tube, 100
μL of standard inoculums (1.5 × 10
8 cfu/mL) was added.
Ciprofloxacin was used as control. Turbidity was observed
after incubating the inoculated tubes at 37°C for 24 h.
In vitro antifungal activity
The antifungal activity of the synthesized compounds
was evaluated by poisoned food technique. The molds
were grown on Sabouraud dextrose agar (SDA) at 25°C
for 7 days and used as inocula. 15 mL of molten SDA
(45°C) was poisoned by the addition of 100 μLv o l u m e
of each compound having concentration of 4.0 mg/mL,
reconstituted in the DMSO, poured into a sterile Petri
plate and allowed it to solidify at room temperature.
The solidified poisoned agar plates were inoculated at
the centre with fungal plugs (8-mm diameter), obtained
from the actively growing colony and incubated at 25°C
for 7 days. DMSO was used as the negative control
whereas fluconazole was used as the positive control.
The experiments were performed in triplicates. Dia-
meter of the fungal colonies was measured and
expressed as percent mycelial inhibition determined by
applying the formula [55].
Inhibition of mycelial growth % =( dc − dt)/dc × 100
where dc average diameter of fungal colony in nega-
tive control plates, dt average diameter of fungal colony
in experimental plates.
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nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-2, 4-dioxothiazolidin-3-
yl)acetate
Additional file 9:
1H NMR Spectra .(5a);
1H NMR of methyl 2-((Z)-2, 4-
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